Skip to main
KMTS

KMTS Stock Forecast & Price Target

KMTS Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 25%
Buy 50%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Kestra Medical Techs is poised for success with their innovative Cardiac Recovery System platform, including their ASSURE WCD, which has shown strong market demand and received FDA approval for a new algorithm. With a Buy rating and positive financial data, this company is well positioned for growth and collaborations with strategic partners only strengthen their potential. Despite potential risks, the positive outlook for Kestra Medical Techs suggests promising returns for investors.

Bears say

Kestra Medical Techs is facing commercial execution risks and potentially low physician adoption and prescription volumes, as well as potential hiccups in billing and collections processes. The company's profitability may be impacted by a higher than anticipated gross margin target and continued progress on prescription fulfillment and revenue cycle management. Additionally, the company may face challenges in expanding insurance coverage for their products, limiting their potential market reach.

KMTS has been analyzed by 4 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 50% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kestra Medical Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kestra Medical Technologies Inc (KMTS) Forecast

Analysts have given KMTS a Buy based on their latest research and market trends.

According to 4 analysts, KMTS has a Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kestra Medical Technologies Inc (KMTS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.